GlaxoSmithKline
- Market cap
- 99.76B
- P/E (TTM)i
- 15.84
- P/Bi
- 4.24
- EPSi
- 3.71
- Div yieldi
- 3.56%
- 52W posi
- 51%
Anonymous reader poll. Unscientific, not investment advice.
GlaxoSmithKline shares were changing hands at 49.80, down 1.82% on the day. At current prices, the business is worth about 99.76B, the #177 most valuable US-listed company we track. Valuation-wise, the P/E sits at 16.22, 17% above the five-year average of 13.86. Income-focused holders are looking at a trailing yield of 3.56% here. Across 1 analysts the consensus rating is Hold, with an average price target of 70.00 (+41%). Over the past year the stock has ranged from 38.98 to 60.12; it now sits 51% up that band.
✦ StockVane Quant Insights how this is computed
- Below its 200-day average or in the bottom third on momentum — the strategy is out of it.
- Signal has read SELL for 3 weeks.
- Recent price momentum is +13.4% on average (3-month/1-year).
- Main-fund capital flow has been a net outflow over the last 45 sessions.
- Analyst tilt is Hold.
- Price is above its 20-day average and below its 60-day average.
- The 20-day average is below the 60-day average, a short-term downtrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 299 U.S. stocks StockVane covers.
Valuation A-
How expensive the stock is versus earnings, sales and its own 5-year history.
| P/E (TTM) | 16.0x | Better than 75% |
| Forward P/E | 13.2x | Better than 78% |
| Price / Sales | 2.3x | Better than 75% |
| P/E vs own 5-yr range | 63rd pctl | Better than 49% |
Growth D+
How fast revenue, profit and free cash flow are compounding.
| Revenue CAGR (3Y) | 3.7% | Better than 31% |
| Net income CAGR (3Y) | -27.4% | Better than 7% |
| Free cash flow CAGR (3Y) | -2.6% | Better than 31% |
Profitability A-
How much profit the business keeps from each dollar of sales and capital.
| Gross margin | 72.4% | Better than 84% |
| Operating margin | 25.5% | Better than 60% |
| Net margin | 17.5% | Better than 54% |
| Return on equity | 38.0% | Better than 77% |
| Return on invested capital | 19.3% | Better than 74% |
Momentum C
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | -0.3% | Better than 40% |
| 6-month return | -6.1% | Better than 14% |
| 12-month return (ex latest month) | 32.3% | Better than 58% |
| Distance below 52-week high | 16.4% | Better than 36% |
Financial Health C-
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 0.8x | Better than 16% |
| Debt to assets | 108.2% | Better than 31% |
| Interest coverage | 11.8x | Better than 57% |
| Free cash flow / net income | 83.2% | Better than 32% |
Analyst View N/A
What the Street thinks: share of Buy ratings and upside to the average target.
Not enough data to grade this factor.
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector, so capital-light software tends to grade lower there than utilities. Recomputed every 6 hours from our market data. Not investment advice.
Price chart
Performance
Key statistics
Price & volume
- Prev close
- 50.72
- Open
- 50.23
- Day range
- 49.67 - 50.74
- Avg price
- 50.11
- Volume
- 2.18M
- Turnover
- 109.43M
- Turnover ratei
- 0.11%
- Volume ratioi
- 0.70
- Amplitudei
- 2.11%
- 52-week rangei
- 38.98 - 60.12
Valuation
- P/Ei
- 13.44
- P/E (TTM)i
- 15.84
- P/Bi
- 4.24
- EPSi
- 3.71
- Book value / shi
- 11.75
- Net profit
- 7.42B
- Net assets
- 23.55B
Share structure
- Market cap
- 99.76B
- Float capi
- 96.65B
- Shares out
- 2.00B
- Float sharesi
- 1.94B
Dividend & listing
- Div yield (TTM)i
- 3.56%
- Dividend (TTM)
- 1.77
- Listing date
- 1970-01-01
17.2% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
-10.21M net over the window
Short interest
- Shares short
- 13.55M
- % of floati
- 0.68%
- Days to coveri
- 4.78
- As of
- 2026-08-31
Frequently asked questions
What is the current stock price of GlaxoSmithKline (GSK)?
GlaxoSmithKline last traded at 49.80. The quote on this page refreshes every few seconds while US markets are open.
What is GlaxoSmithKline's market cap?
About 99.76B.
What is the P/E ratio of GlaxoSmithKline?
The trailing twelve-month P/E is 15.84, above its own 5-year average of 13.86 — in the middle of its historical range (62.84% percentile). See the Valuation tab for the full history.
Does GlaxoSmithKline pay a dividend?
Yes. The trailing dividend yield is 3.56%. See the Dividends tab for the full payment history.
Is GlaxoSmithKline a buy according to analysts?
The consensus of 1 analysts is a Hold rating, with an average 12-month price target of 70.00, which implies 40.6% upside from the current price. This is not investment advice.
Quote time 2026-09-23 15:08:54 · For reference only, not investment advice.